GlassScriptPhysician profile
Firas Marayati
NPI 1316148653
$884.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $126 · 2021: $195 · 2022: $214.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $314.83 | 2019-2022 | |
| Amgen INC. | $148.67 | 2019-2021 | |
| Horizon Therapeutics Plc | $82.41 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.18 | 2020-2022 | |
| Glaxosmithkline, LLC. | $53.95 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $51.95 | 2021-2022 | |
| Vifor Pharma, INC. | $36.39 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $31.98 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $24.97 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.70 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.49 | 2022 | |
| Shire North American Group INC | $14.02 | 2019 | |
| Daiichi Sankyo INC. | $13.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Marayati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.